The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis
Makaleler > Tam Makale · 2013
Yazarlar: Şenol Kobak, Ahmet Karaarslan, Fahrettin Oksel
Case Reports in Rheumatology, Uluslararası, 2013, cilt 2013, ss 1-4
DOI: 10.1155/2013/792526
Özet
Rheumatoid arthritis (RA) is considered as a connective tissue disease while ankylosing spondylitis (AS) is a prototype of spondyloarthritis. These diseases are seen concomitantly only very rarely. Also, rituximab has proven efficacy in the treatment of RA while its role in the treatment of AS is unclear. In this presentation, the concomitant presence of RA and AS in a 43-year-old male patient as well as the efficacy and safety of rituximab is discussed. Rituximab was given due to lack of response to treatment with anti-TNF-alpha. Evaluations made at the 6th and 12th months of treatment showed complete response for RA and partial response for AS.